covid-19-vaccines

Documents about covid-19-vaccines

• COVID-19 Vaccines in Patients With Chronic Liver Disease#238187ClinicalTrials.gov
• COVID-19 vaccine trial ethics once we have efficacious vaccines#776793PhilArchive
• The impact of COVID-19 vaccines on reinfection in Vietnam and Indonesia: the role of vaccine technology and dosage#191054Figshare
• Dissecting Human Immune Responses to Infection With Influenza or SARS-CoV-2#898946ClinicalTrials.gov
• Effectiveness of 2025-2026 mRNA-1283 and BNT162b2 COVID-19 Vaccines Against COVID-19 Related Hospitalizations and Medically-Attended COVID-19 Among Adults Aged >= 65 years in the United States#189385bioRxiv / medRxiv
• Assessing Immune Response of Different COVID-19 Vaccines in Older Adults#853054ClinicalTrials.gov
• Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study#839270ClinicalTrials.gov
• SAFETY, EFFICACY, AND IMMUNOGENICITY OF SARS-COV-2 MRNA VACCINES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS#334543ScholarBank@NUS
• Documentation Gap Analysis: Independent Audit of TGA COVID-19 Vaccine Safety Monitoring Plan#209787OSF
• Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic#373669ClinicalTrials.gov
• The Role of BCG Vaccine in the Clinical Evolution of COVID-19 and in the Efficacy of Anti-SARS-CoV-2 Vaccines#432930ClinicalTrials.gov
• NDV-HXP-S Vaccine Clinical Trial (COVIVAC)#238188ClinicalTrials.gov
• Mix and Match Heterologous Prime-Boost Study Using Approved COVID-19 Vaccines#405207ClinicalTrials.gov
• PREPARE-iVAC Trial#454081ClinicalTrials.gov
• Rethinking vaccine mandates through the lens of penalties and incentives: A 7S framework approach.#358771PubMed
• Factors Influencing the Acceptance of COVID-19 Vaccines in a Country with a High Vaccination Rate#948931Repositorio de Universidad Autónoma de Chile.
• A Study of Ad26.COV2.S in Healthy Adults (COVID-19)#474820ClinicalTrials.gov
• The effectiveness of COVID-19 vaccines and the added benefit of booster doses in Hessen, Germany, during the COVID-19 pandemic: Results from a vaccinated-only study#5124Europe PMC
• Prospective Evaluation of COVID-19 Vaccine in Transplant Recipients: A National Strategy [PREVenT-COVID, study data contributed to the CITF Databank]#411198Borealis Dataverse OAI Archive
• Avaliação da intenção dos brasileiros em vacinar para prevenção da Covid-19: Estudo TREND#1028970Arca Dados Dataverse OAI Archive
• COVID-19, Fake News, and Vaccines: Should Regulation Be Implemented?#23839CiNii
• Trends in the Development of Drugs and Vaccines for the Treatment of COVID-19#69813J-STAGE (Japan)
• Comparative effectiveness of mandates and financial policies targeting COVID-19 vaccine hesitancy: A randomized, controlled survey experiment#169580Scholarly Commons at Boston University School of Law
• Candesartan, Metoprolol and Rosuvastatin Associated to Lower 30-Days Mortality in Adult COVID-19 Patients - A Register Study in Finland before COVID-19 Vaccines.#224797NCBI PubMed Central
• Psychosocial factors associated with the intention to get a COVID-19 booster vaccine: evidence from a low-income country#654621Repositorio UCB
• Immunogenicity and Reactogenicity Following a Booster Dose of COVID-19 mRNA Vaccine (Pfizer-BioNtech) and Two Adjuvanted Sub-unit Vaccines (SP/GSK) Administered in Adults Who Received 2 Doses of Pfizer-BioNTech mRNA Vaccine as a Primary Vaccination#905641ClinicalTrials.gov
• A scoping review of vaccine certificate implementation in Canada and OECD countries during the COVID-19 pandemic: Outcomes and lessons learned.#9593PubMed
• Documentation Gap Analysis: Independent Audit of TGA COVID-19 Vaccine Safety Monitoring Plan#485988SocArXiv
• Population-level behavioral and structural drivers of COVID-19 vaccine uptake in the US#385427PLOS
• A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines#1007281ClinicalTrials.gov
• Annexes to the recommendations for use of the Biological E Limited’s Corbevax (BECOV-2) vaccine against COVID-19: grading of evidence, evidence to recommendations tables, first issued 25 September 2023#432273WHO IRIS
• Retrospective Study of COVID-19 Vaccines in Patients Undergoing Immunotherapy for Cancer.#303727ClinicalTrials.gov
• Off-Label Prescription of COVID-19 Vaccines in Children: Clinical, Ethical, and Legal Issues#760084PhilArchive
• Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial#314320ClinicalTrials.gov
• Development of a COVID-19 Vaccination Anxiety Scale to measure COVID-19 vaccine anxiety in Japanese adults#348423PLOS
• A Clinical Observational Study of SARS-CoV-2 Specific CD8 T-Cell Responses to COVID-19 Vaccines in Humans#827136ClinicalTrials.gov
• Phase 1 Trial of ChAd68 and Ad5 Adenovirus COVID-19 Vaccines Delivered by Aerosol#830961ClinicalTrials.gov
• Safety Study About the mRNA Vaccines Against COVID-19 in Children (PEDIVACOV-HCSC)#866914ClinicalTrials.gov
• Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States#885786ClinicalTrials.gov
• Efficacy of Vaccination Against COVID-19 in Patients Presenting a Neuromuscular Disease With Severe Amyotrophy#892362ClinicalTrials.gov
• Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines#125907ClinicalTrials.gov
• Reactogenicity and Immunogenicity of Third Dose Vaccine Booster Following Two Doses of Inactivated Vaccines#849354ClinicalTrials.gov
• Antibody Response to COVID-19 Vaccines in Liver Disease Patients#891098ClinicalTrials.gov
• Social Value, Beneficial Information, and Obligations to Participants in a Trial of Novel COVID-19 Vaccines#97061PhilArchive
• Hacia una vacuna contra el Coronavirus causante de la Covid-19#370158DSpace
• Association between COVID-19 vaccines and herpes zoster and urticaria: a UK population-based self-controlled case series study#477534University of Nottingham Repository
• Irregular migrants' experiences of health disparities while living in informal settlements during the COVID-19 pandemic#935803Repositorio de Universidad Autónoma de Chile.
• Interim Effectiveness of 2025–2026 mRNA-1283 and BNT162b2 COVID-19 Vaccines Against COVID-19-Related Outcomes Among Adults Aged ≥ 65 Years in the United States#456078Springer Nature OA
• DOES COVID-19 VACCINE INFORMATION HAVE SPILLOVER EFFECTS ON ACCEPTANCE OF ESTABLISHED AND NOVEL VACCINES? EVIDENCE FROM TWO LONGITUDINAL AND TWO EXPERIMENTAL STUDIES#929241ScholarlyCommons
• Glucoside- and Rutinoside-rich Crude Material for Relieving Side Effects of COVID-19 Vaccines#651127ClinicalTrials.gov